What's New in Our Cath Lab of Tomorrow?
Saturday, March 13, 3:00 PM - 4:00 PM
Usually, when speaking about the cath lab of tomorrow, you’d expect to hear about hybrid suites and high-definition 50-foot monitors. Not in this session, which might be better titled: New Practices in Our Cath Lab of Tomorrow.
With the arrival of prasugrel into the cath lab, many interventional cardiologists might be wondering what that means for clopidogrel and other thienopyridines. In this session, expect that question to be answered. You will hear about these new and emerging treatment options, which will be compared and contrasted to existing treatments.
While warfarin has served the cardiology community well for many years, the drug is associated with food interactions and routine blood-coagulation testing. Patients with atrial fibrillation are routinely prescribed chronic warfarin and they sometimes don’t comply very well. One way to decrease patients’ reliance on warfarin and keep the risk of stroke low is by blocking the left atrial appendage. This session will give an overview of the Watchman, a device intended to block blood flow from the left atrial appendage. An FDA panel last year narrowly voted to approve the device, but the agency has yet to act on its suggestion. It might be a good idea to anticipate FDA approval and, therefore, this session could give you all you need to know about the device so you can incorporate it into your practice.
Another technique that will be commonplace in the cath lab of tomorrow is transcatheter valve replacement. You most likely won’t be able to turn a corner at ACC.10 without hearing about this topic. Several valve devices are approved in Europe, but are not yet approved in the U.S., although there are several FDA-approved trials ongoing. Get a jump start on this exciting technology in this session and learn about mitral valve edge-to-edge repair.
Location: Room B406
Speaker Information:
Steven P. Dunn, MD, Lexington, Ky.
Peter C. Block, MD, Atlanta
Howard C. Herrmann, MD, Philadelphia
Usually, when speaking about the cath lab of tomorrow, you’d expect to hear about hybrid suites and high-definition 50-foot monitors. Not in this session, which might be better titled: New Practices in Our Cath Lab of Tomorrow.
With the arrival of prasugrel into the cath lab, many interventional cardiologists might be wondering what that means for clopidogrel and other thienopyridines. In this session, expect that question to be answered. You will hear about these new and emerging treatment options, which will be compared and contrasted to existing treatments.
While warfarin has served the cardiology community well for many years, the drug is associated with food interactions and routine blood-coagulation testing. Patients with atrial fibrillation are routinely prescribed chronic warfarin and they sometimes don’t comply very well. One way to decrease patients’ reliance on warfarin and keep the risk of stroke low is by blocking the left atrial appendage. This session will give an overview of the Watchman, a device intended to block blood flow from the left atrial appendage. An FDA panel last year narrowly voted to approve the device, but the agency has yet to act on its suggestion. It might be a good idea to anticipate FDA approval and, therefore, this session could give you all you need to know about the device so you can incorporate it into your practice.
Another technique that will be commonplace in the cath lab of tomorrow is transcatheter valve replacement. You most likely won’t be able to turn a corner at ACC.10 without hearing about this topic. Several valve devices are approved in Europe, but are not yet approved in the U.S., although there are several FDA-approved trials ongoing. Get a jump start on this exciting technology in this session and learn about mitral valve edge-to-edge repair.
Location: Room B406
Speaker Information:
Steven P. Dunn, MD, Lexington, Ky.
Peter C. Block, MD, Atlanta
Howard C. Herrmann, MD, Philadelphia